Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

The injectable drug Ozempic is shown Saturday ... The 503As, however, could exploit a loophole: They can still make semaglutide copies that are not "essential copies" of the drug.

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

May 16 (Reuters) - Ozempic-maker Novo Nordisk (NOVOb.CO ... losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly (LLY.N), opens new tab.

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is ...

The runaway success of GLP-1 drugs made Novo Nordisk, a Danish drugmaker, the top company in Europe by market cap. These medications, injected into the body, mimic a hormone that regulates blood ...